

Title (en)

MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF

Title (de)

MALEATSALZE VON (E)-N-[4-[3-CHLOR-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-CHINOLINYL]-4-(DIMETHYLAMINO)-2-BUTENAMID UND KRISTALLINE FORMEN DAVON

Title (fr)

SELS MALÉATES DE (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMÉTHOXY)ANILINO]-3-CYANO-7-ÉTHOXY-6-QUINOLINYL}-4-(DIMÉTHYLAMINO)-2-BUTÉNAMIDE ET LEURS FORMES CRISTALLINES

Publication

EP 2212311 A2 20100804 (EN)

Application

EP 08840120 A 20081016

Priority

- US 2008080130 W 20081016
- US 12479607 P 20071017

Abstract (en)

[origin: WO2009052264A2] The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.

IPC 8 full level

C07D 401/12 (2006.01); **A61K 31/404** (2006.01); **A61P 35/00** (2006.01)

CPC (source: CN EP IL KR RU US)

A61K 31/4709 (2013.01 - CN EP IL KR RU US); **A61P 1/04** (2018.01 - EP IL); **A61P 1/08** (2018.01 - EP IL); **A61P 1/12** (2018.01 - EP IL); **A61P 11/00** (2018.01 - EP IL); **A61P 13/08** (2018.01 - EP IL); **A61P 13/10** (2018.01 - EP IL); **A61P 13/12** (2018.01 - EP IL); **A61P 15/00** (2018.01 - EP IL); **A61P 17/00** (2018.01 - EP IL); **A61P 35/00** (2018.01 - EP IL); **A61P 43/00** (2018.01 - EP IL); **C07C 51/412** (2013.01 - IL US); **C07C 57/145** (2013.01 - IL US); **C07D 401/12** (2013.01 - CN EP IL KR RU US); **C07D 401/14** (2013.01 - CN)

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA MK RS

DOCDB simple family (publication)

WO 2009052264 A2 20090423; **WO 2009052264 A3 20090611**; AR 068932 A1 20091216; AR 103866 A2 20170607; AU 2008312474 A1 20090423; AU 2008312474 B2 20140116; BR 122019023745 B1 20210202; BR 122019023745 B8 20210727; BR P10818464 A2 20160105; BR P10818464 B1 20200630; BR P10818464 B8 20210525; CA 2702930 A1 20090423; CA 2702930 C 20160705; CA 2928071 A1 20090423; CA 2928071 C 20170425; CL 2008003088 A1 20090320; CN 101918390 A 20101215; CN 101918390 B 20140618; CN 103554086 A 20140205; CN 106822127 A 20170613; CN 106822127 B 20220729; CN 110452221 A 20191115; CN 116715653 A 20230908; CN 116715654 A 20230908; CN 117143077 A 20231201; EP 2212311 A2 20100804; EP 2258698 A2 20101208; EP 2258698 A3 20110216; EP 2537843 A2 20121226; EP 2537843 A3 20130313; EP 2537843 B1 20160914; EP 2617719 A1 20130724; EP 2617719 B1 20160511; EP 2626353 A1 20130814; EP 2626353 B1 20161123; EP 3088398 A1 20161102; ES 2586435 T3 20161014; ES 2602123 T3 20170217; ES 2612273 T3 20170516; HK 1146405 A1 20110603; HK 1187619 A1 20140411; IL 205024 A0 20101130; IL 205024 B 20180430; IL 258440 A 20180531; IL 308687 A 20240101; IN 1135DEN2015 A 20150710; JP 2011063610 A 20110331; JP 2011500712 A 20110106; JP 2012067131 A 20120405; JP 2013053170 A 20130321; JP 2015127352 A 20150709; JP 2017043640 A 20170302; JP 2018109071 A 20180712; JP 2020111606 A 20200727; JP 2021185200 A 20211209; JP 2023164747 A 20231110; JP 5965640 B2 20160810; JP 6412090 B2 20181024; KR 101208301 B1 20121205; KR 20100069708 A 20100624; KR 20130025862 A 20130312; KR 20150039872 A 20150413; KR 20160136474 A 20161129; KR 20180041753 A 20180424; MX 2010004173 A 20100430; MX 2021013585 A 20220518; MX 342681 B 20161007; MX 349332 B 20170721; NZ 600349 A 20131220; NZ 616136 A 20150424; NZ 705641 A 20160729; PA 8800701 A1 20090515; RU 2010115089 A 20111127; RU 2012126864 A 20140110; RU 2463300 C2 20121010; RU 2621719 C2 20170607; SG 10201900175T A 20190227; SG 185312 A1 20121129; TW 200934761 A 20090816; US 10035788 B2 20180731; US 2009176827 A1 20090709; US 2011313166 A1 20111222; US 2012289545 A1 20121115; US 2013281488 A1 20131024; US 2016068511 A1 20160310; US 2017320852 A1 20171109; US 8022216 B2 20110920; US 8173814 B2 20120508; US 8394959 B2 20130312; US 9139558 B2 20150922; US 9630946 B2 20170425

DOCDB simple family (application)

US 2008080130 W 20081016; AR P080104565 A 20081017; AR P160100590 A 20160304; AU 2008312474 A 20081016; BR 122019023745 A 20081016; BR P10818464 A 20081016; CA 2702930 A 20081016; CA 2928071 A 20081016; CL 2008003088 A 20081017; CN 200880118789 A 20081016; CN 201310576791 A 20081016; CN 201710057547 A 20081016; CN 201910667051 A 20081016; CN 202310689097 A 20081016; CN 202310690478 A 20081016; CN 202310691104 A 20081016; EP 08840120 A 20081016; EP 10173679 A 20081016; EP 12172411 A 20081016; EP 13150905 A 20081016; EP 13150913 A 20081016; EP 16167319 A 20081016; ES 12172411 T 20081016; ES 13150905 T 20081016; ES 13150913 T 20081016; HK 11100555 A 20110120; HK 14100720 A 20140123; IL 20502410 A 20100412; IL 25844018 A 20180328; IL 30868723 A 20231119; IN 1135DEN2015 A 20150212; JP 2010258729 A 20101119; JP 2010530105 A 20081016; JP 2011289220 A 20111228; JP 2012279650 A 20121221; JP 2015080748 A 20150410; JP 2016238151 A 20161208; JP 2018079067 A 20180417; JP 2020070281 A 20200409; JP 2021146090 A 20210908; JP 2023160192 A 20230925; KR 20107010637 A 20081016; KR 20127017202 A 20081016; KR 20157007530 A 20081016; KR 20167032469 A 20081016; KR 20187008867 A 20081016; MX 2010004173 A 20081016; MX 2012006904 A 20081016; MX 2016009168 A 20081016; MX 2021013585 A 20100416; NZ 60034908 A 20081016; NZ 61613608 A 20081016; NZ 70564108 A 20081016; PA 8800701 A 20081017; RU 2010115089 A 20081016; RU 2012126864 A 20120628; SG 10201900175T A 20081016; SG 2012077145 A 20081016; TW 97139993 A 20081017; US 201113181375 A 20110712; US 201213441168 A 20120406; US 201313765356 A 20130212; US 201514825612 A 20150813; US 201715463998 A 20170320; US 25192408 A 20081015